Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19610168 | 0.83 | KDM1A (0.61) | KDM1ARAB9ATSHR | |
| SCHEMBL19610322 | 0.82 | KDM1A (0.58) | KDM1ANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19610374 | 0.80 | KDM1A (0.60) | KDM1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19610291 | 0.80 | KDM1A (0.62) | KDM1ANPC1RAB9AMAPT | |
| SCHEMBL19610239 | 0.80 | KDM1A (0.60) | KDM1ANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19610181 | 0.79 | KDM1A (0.47) | KDM1ARCOR1TSHR | |
| SCHEMBL19610283 | 0.78 | KDM1A (0.61) | KDM1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20985143 | 0.76 | KDM1A (0.49) | KDM1ANPC1RAB9AMAPT | |
| SCHEMBL19610440 | 0.75 | KDM1A (0.56) | KDM1ANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19610172 | 0.71 | KDM1A (0.56) | KDM1ANPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458460-B1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-12-09 | — | — | EP | claimed |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-02-18 | — | — | US | claimed |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-05-23 | — | — | US | claimed |
| EP-3458460-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2019-03-27 | — | — | EP | claimed |
| WO-2017198780-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-11-23 | — | — | WO | claimed |
| EP-3246330-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2017-11-22 | — | — | EP | claimed |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-03-30 | — | — | US | disclosed |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-03-30 | — | — | US | disclosed |
| EP-3458460-B1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-12-09 | — | — | EP | disclosed |
| EP-3458460-B1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-12-09 | — | — | EP | disclosed |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-24 | — | — | US | disclosed |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-24 | — | — | US | disclosed |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-05-23 | — | — | US | disclosed |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-05-23 | — | — | US | disclosed |
| EP-3458460-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198780-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-11-23 | — | — | WO | disclosed |
| EP-3246330-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2017-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, DOT1L | KDM1A 2/4885NPC1 3364/4885RAB9A 2538/4885 |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | DOT1L, KDM1B, KDM1A | KDM1A 3/4885NPC1 3295/4885RAB9A 2718/4885 |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | KDM1B, KDM1A, DOT1L | KDM1A 2/4885NPC1 3364/4885RAB9A 2538/4885 |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | DOT1L, KDM1B, KDM1A | KDM1A 3/4885NPC1 3295/4885RAB9A 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.